Skip to main content

Table 2 Demographic and clinical characteristics of HER2 positive Breast Cancer Patients

From: Frequency and clinical characteristics of HER2 over-expressed breast cancer in Saudi Arabia: a retrospective study

Demographic and clinical characteristics

Total

N = 348

Age at study inclusion (years), n = 348

Mean ± SD

54.07 ± 11.55

Age at breast cancer diagnosis (years), n = 344

Mean ± SD

48.14 ± 11.67

Sex, n = 348

Male

3 (0.9%)

Female

345 (99.1%)

Nationality, n = 348

Saudi Arabian

322 (92.5%)

Other

26 (7.5%)

Body Mass Index (kg/m2), n = 262

Mean ± SD

30.56 ± 6.35

Breast cancer stage based on TNM classification at diagnosis, n = 260

Stage I

19 (7.3%)

Stage II

103 (39.6%)

Stage III A

57 (21.9%)

Stage III B

47 (18.1%)

Stage IV

34 (13.1%)

Metastatic sites, n = 30

Bone

15 (50.0%)

Lung

13 (43.3%)

Liver

13 (43.3%)

Lymph node

4 (13.3%)

Brain

3 (10.0%)

Ovaries

1 (3.3%)

Peritoneum

1 (3.3%)

Primary cancer site, n = 348

Right

175 (50.3%)

Left

164 (47.1%)

Bilateral

8 (2.3%)

Unknown

1 (0.3%)

Performance status, n = 187

Performance status = 0

20 (10.7%)

Performance status = 1

122 (65.2%)

Performance status = 2

31 (16.6%)

Performance status = 3

9 (4.8%)

Performance status = 4

5 (2.7%)

Performance status = 5

0 (0.0%)

Site of biopsy, n = 348

Primary tumor site

328 (94.3%)

Metastatic tumor site

15 (4.3%)

Unknown, not recorded

5 (1.4%)

HER2 test method, n = 348

FISH

53 (15.3%)

IHC

294 (84.7%)

Curative intent surgery performed, n = 348

Yes

293 (84.2%)

No

55 (15.8%)

If Yes, tumor size (cm), n = 264

Mean ± SD

3.5 ± 2.5

Breast cancer pathology, n = 283

Infiltrating ductal carcinoma

263 (92.9%)

Infiltrating lobular carcinoma

0 (0.0%)

Medullary carcinoma

0 (0.0%)

Inflammatory breast cancer

2 (0.7%)

Tubular carcinoma

1 (0.4%)

Mucinous carcinoma

2 (0.7%)

Ductal carcinoma in situ

13 (4.6%)

Invasive ductal carcinoma

2 (0.7%)

Hormone-receptor status, n = 340

ER-/PR-

144 (42.4%)

ER + and/or PR + 

196 (57.6%)

Tumor margins, n = 265

Negative

245 (92.5%)

Positive

20 (7.5%)

More than one tumor in the breast, n = 346

Yes

58 (16.8%)

No

288 (83.2%)

If Yes, tumor origin, n = 53

Multifocal breast cancer

33 (62.3%)

Multicentric breast cancer

20 (37.7%)

Lymphovascular invasion, n = 289

Yes

121 (41.9%)

No

168 (58.3%)

Axillary lymph nodes examined (sentinel, sampling, dissection), n = 313

Yes

256 (81.8%)

No

57 (18.2%)

Number of lymph nodes examined, n = 254

Mean ± SD

14.5 ± 11.2

Number of lymph nodes involved, n = 253

Mean ± SD

3.7 ± 7.6

Clinical response at last patient evaluation, n = 217

Stable disease

61 (28.1%)

Progressive disease

72 (33.2%)

Partial response

4 (1.8%)

Complete response

80 (36.9%)

  1. SD standard deviation, FISH fluorescent in situ hybridization, IHC ImmunoHistoChemistry, ER estrogen receptor, PR progesterone receptor